



IJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 **Issue:** III **Month of publication:** March 2024

DOI: <https://doi.org/10.22214/ijraset.2024.59329>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Congenital Insensitivity to Pain with Anhidrosis (CIPA): A Comprehensive Review

Sonali Gadade¹, Pravin Budhe², Monika Dombale³

Mandesh Institute of Pharmaceutical Science and Reserch Center, Mhaswad

Abstract: *Congenital Insensitivity to Pain with Anhidrosis (CIPA), also known as hereditary sensory and autonomic neuropathy type IV (HSAN IV), is a rare genetic disorder characterized by the inability to perceive pain and a lack of sweat (anhidrosis). This review aims to provide a comprehensive understanding of CIPA, including its clinical features, genetic basis, diagnostic challenges, and management strategies.*

I. INTRODUCTION

CIPA is an extremely rare autosomal receding disorder that affects the sensory and autonomic nervous systems. Individuals with CIPA are unable to feel physical pain, which may lead to severe injuries and infections due to the absence of protective responses to harmful stimuli. Additionally, the lack of sweating (anhidrosis) can result in difficulties regulating body temperature.

Congenital insensitivity to pain is a rare disorder, first stated in 1932 by Dearbron as Congenital pure analgesia.

However, in a patient with CIPA, the gene encoding the Neurotrophic Tyrosine-Kinase receptor (NTRK1 gene), is redone in a way that interferes and halts the autophosphorylation process, therefore stopping signals of pain and temperature from being sent to the brain. [1]

II. CLINICAL FEATURES

Congenital Insensitivity to Pain with Anhidrosis (CIPA) is characterized by a definite set of clinical features that differentiate it from other sensory neuropathies. Understanding these features is crucial for early diagnosis and management. The clinical presentation of CIPA includes:

A. Absence of Pain Sensation

Individuals with CIPA lack the ability to apperceive pain from birth.

Pain insensitivity is global, encompassing various types of stimuli, including temperature extremes, pressure, and injuries.

Children with CIPA may exhibit self-mutilating behaviors, such as biting their own fingers or lips, as they are unaware of the harm caused.

B. Anhidrosis (Lack of Sweating)

An inability to sweat, leading to diminish thermoregulation.

The absence of sweating can result in a susceptibility to hyperthermia during physical activity or exposure to warm environments.

C. Recurrent Injuries and Trauma

Due to the absence of pain perception, individuals with CIPA often experience periodic injuries and trauma.

Fractures, burns, and wounds may go unnoticed, leading to delayed or absent medical intervention.

D. Oral and Musculoskeletal Issues

Self-mutilation involving the oral cavity, including tongue biting and lip injuries.

Musculoskeletal problems may rise due to repeated injuries, leading to joint deformities and impaired motor development.

E. Autonomic Nervous System Dysfunction

CIPA affects the autonomic nervous system, leading to abnormalities in blood pressure regulation and heart rate variability.

Gastrointestinal and genitourinary abnormalities may also be noticed.

F. Delayed Motor Development

Children with CIPA may experience delays in reaching developmental milestones, such as sitting, crawling, and walking. The lack of pain feedback can impact motor skill gain.

G. Chronic Infections and Dental Issues

Insensitivity to pain may result in chronic infections, particularly in areas prone to injuries. Dental problems are common due to the inability to sense teeth ache, leading to delayed dental care.

H. Psychological and Behavioral Challenges

Individuals with CIPA may face challenges related to psychosocial well-being. Coping with pain insensitivity and navigating a world designed around pain attention can contribute to psychological stress. Understanding the clinical features of CIPA is essential for healthcare professionals to facilitate early diagnosis and implement appropriate management strategies. Due to the rarity of the condition, a multidisciplinary approach involving neurologists, geneticists, and pain consultant is often necessary to provide comprehensive care for individuals with CIPA. [2]

III. GENETIC BASIS

CIPA is primarily caused by mutation in the *NTRK1* gene, which encodes the receptor tyrosine kinase for nerve growth factor (NGF). NGF is crucial for the development and survival of sensory and sympathetic neurons. Mutations in *NTRK1* disrupt the normal functioning of these neurons, leading to the characteristic features of CIPA.

Congenital Insensitivity to Pain with Anhidrosis (CIPA), also known as hereditary sensory and autonomic neuropathy type IV (HSAN IV), is primarily accredited to mutations in the *NTRK1* gene. Here is a more detailed exploration of the genetic basis of CIPA:

A. Identification of the *NTRK1* Gene

- The *NTRK1* gene, located on chromosome 1q21-q22, encodes the TrkA receptor, a tyrosine kinase receptor essential for the mandatory and signaling of nerve growth factor (NGF).
- NGF, a neurotrophin, plays a crucial role in the development, survival, and maintenance of sensory and sympathetic neurons.

B. Receptor Tyrosine Kinase (TrkA) and NGF Interaction

- TrkA is a high-affinity receptor for NGF, facilitating the binding and activation of NGF.
- The binding of NGF to TrkA initiates intracellular signaling cascades that modulate cell growth, differentiation, and survival.

C. Functional Consequences of *NTRK1* Mutations

- Mutations in the *NTRK1* gene disrupt the normal function of the TrkA receptor, leading to altered cellular responses to NGF.
- These mutations may result in the absence or reduced effectiveness of NGF waving in sensory and sympathetic neurons.

D. Impact on Neuronal Development and Survival

- During embryonic and postnatal development, NGF-TrkA signaling is critical for the growth, survival, and differentiation of sensory and sympathetic neurons.
- Mutations in *NTRK1* compromise these processes, contributing to the characteristic features of CIPA.

E. Types of Mutations

- Mutations in *NTRK1* associated with CIPA can include wrong sense mutations, nonsense mutations, frameshift mutations, and other structural variations.
- The diversity of mutations contributes to the phenotypic variability observed among individuals with CIPA.

F. Autosomal Recessive Inheritance

- CIPA follows an autosomal latent pattern of inheritance.
- Affected individuals inherit two copies of the mutated *NTRK1* gene, one from each parent, leading to the manifestation of the disorder.

G. Phenotypic Variability

- The specific mutation and its location within the NTRK1 gene can influence the acuteness and presentation of CIPA.
- Variability in clinical features may be observed among individuals with different mutations. [3]

IV. DIAGNOSIS

Diagnosing CIPA can be challenging, and a combination of clinical, neurophysiological, and genetic testing is often required. Neurophysiological studies, such as nerve conduction studies and skin biopsy for nerve fiber analysis, can contribute to the diagnosis. Genetic testing, including sequence of the NTRK1 gene, is crucial for confirming the presence of mutations.

Diagnosing Congenital Insensitivity to Pain with Anhidrosis (CIPA) requires a combination of clinical evaluation, laboratory tests, and genetic analysis. Due to its rarity and unique clinical features, a multidisciplinary approach including neurologists, geneticists, and other specialists is often necessary. Here is an overview of the diagnostic process:

A. Clinical Evaluation

- **Medical History:** A detailed medical history is crucial, focusing on the patient's pain perception, history of injuries, and patterns of react to environmental stimuli.
- **Family History:** Inquiring about a family history of similar symptoms helps establish the genetic nature of CIPA.

B. Neurological Examination

- A thorough neurological exam assesses sensory and motor functions, reflexes, and autonomic nervous system responses.
- Specific attention is given to the absence of pain sensation and anhidrosis.

C. Sweat Test

- Anhidrosis, the inability to sweat, is a hallmark feature of CIPA. Sweat tests, such as the iodine-starch test, can be performed to confirm the absence of sweat in response to thermal stimuli.

D. Pain Perception Tests

- Various pain perception tests, include thermal and mechanical stimuli, may be conducted to assess the patient's ability to perceive pain.
- Lack of normal response to these stimuli contributes to the diagnostic criteria.

E. Genetic Testing

- **NTRK1 Gene Sequencing:** Molecular genetics testing involves sequencing the NTRK1 gene to identify mutation. This is a definitive method for confirming the diagnosis of CIPA.
- **Targeted Genetic Panels:** In cases where clinical suspicion is high, targeted genetics panels may be used to assess a broader range of genes associated with sensory neuropathies.

F. Skin Biopsy

- A skin biopsy may be performed to examine nerve fiber in the skin. The absence or abnormalities of nerve fibers can support the diagnosis of CIPA.

G. Imaging Studies

- Imaging studies, such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, may be conducted to assess the musculoskeletal system and detect any abnormalities resulting from recurrent injurie.

H. Autonomic Function Tests

- Evaluating autonomic function through tests like heart rate variability analysis can provide additional insight into the dysregulation of the autonomic nervous system in individual with CIPA.

I. Differential Diagnosis

- It's important to differentiate CIPA from other condition with similar symptoms, such as congenital sensory neuropathies or autoimmune disorders affecting nervous system. [4]

V. MANAGEMENT

The managements of Congenital Insensitivity to Pain with Anhidrosis (CIPA) is primarily symptomatic and aims to address the challenges associated with pain insensitivity, anhidrosis, and the potential complications arising from these features. Due to the rarity of CIPA and the absence of a cure, a multidisciplinary approach is often necessary to provide comprehensive care. Here are key aspect of the management of individuals with CIPA:

A. Pain Management

- Preventive Measures: Due to the absence of pain perception, preventive measures are essential to avoid injuries. This includes protective equipment and modifying the environment to reduce potential hazard.
- Regular Monitoring: Regular medical check-ups are crucial to identify and address injuries or condition that may go unnoticed by the individuals.

B. Temperature Regulation

- Environmental Modifications: Individuals with CIPA are prone to hyperthermia due to the lack of sweatings. Environmental modifications, such as staying in a cool environment and using cooling devices, help regulate body temperature.
- Monitoring for Hyperthermia: Caregivers and healthcare providers should be vigilant in monitoring for sign of hyperthermia, especially during physical activities.

C. Skin and Musculoskeletal Care

- Regular Skin Checks: Regular skin examination are necessary to identify injuries, wounds, or infections that may occur without the individual's awareness.
- Physical Therapy: Physical therapy may be beneficial to addresses musculoskeletal issues and promote motor development.

D. Dental Care

- Regular Dental Check-ups: Due to the lack of pain perception, regular dental check-up are essential to identify and address dental issues promptly.

E. Psychosocial Support

- Counseling and Support Groups: Individuals with CIPA and their families may benefit from counseling and support groups to address the psychological and emotional challenges associated with living with a rare conditions.

F. Genetic Counseling

- Family Planning: Genetic counseling is important for individual with CIPA and their families, especially for those considering family planning. It helps in understanding the risk of passing on the condition to future generations.

G. Educational Support

- Special Education: Children with CIPA may benefit from specials seducation programs that cater to their unique need and challenges.

H. Research Participation

- Clinical Trials: Participation in clinical trials and research studies may provide individuals with CIPA access to potential therapeutic interventions and contributes to advancing knowledge about the conditions.

I. Symptomatic Treatment:

- Treatment of Infections and Injuries: Prompt and aggressive treatments of infections and injurie is necessary to prevent complications.
- Pharmacological Management: Symptomatic relief, such as analgesics for other discomforts, may be considered under close medical supervisions.

It's crucial for healthcare providers to work collaboratively with individual with CIPA and their families to tailor management strategies to the specific needs and challenges presented by this rare genetics disorder. Regular follow-ups and a proactive approach to addressing potential issues are key components of effective CIPA managements. [5]

VI. CHALLENGES AND FUTURE DIRECTIONS

Despite advances in our understanding of CIPA, challenges remain in its diagnosis and management. Further research is needed to explore potential therapeutic interventions to improve the quality of life for individuals with CIPA. Additionally, raising awareness about the condition is crucial for early identification and intervention. [6]

VII. CONCLUSION

Congenital Insensitivity to Pain with Anhidrosis is a rare and complex disorder that poses significant challenges in diagnosis and management. This review highlights the clinical features, genetic basis, diagnostic approaches, and current management strategies for CIPA. Continued research is essential to enhance our understanding of this condition and develop effective therapeutic interventions.

This study shows that we should notice the combination of some different signs and symptoms to find this syndromic disease. [7]

REFERENCES

- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564101/> [Iran J Pediatr](#). 2012 Sep; 22(3): 412–416.
- [1] Dearborn G. A case of congenital pure analgesia. *J Nerv Ment Dis*. 1932;75:612–5. [[Google Scholar](#)]
 - [2] Rasmussen P. The congenital insensitivity-to-pain syndrome (analgesia congenita) *Int J Paediatr Dent*. 1996;6:117–22. [[PubMed](#)] [[Google Scholar](#)]. [8]
 - [3] Hall KH. *Paediatric Orofacial Medicine and Pathology*. 3rd ed. London: Chapman & Hall Medical; 1994. pp. 330–5. [[Google Scholar](#)]
 - [4] Narayanan V. Oral and maxillofacial manifestations of hereditary sensory neuropathy. *Br J Oral Maxillofac Surg*. 1996;34:446–9. [[PubMed](#)] [[Google Scholar](#)]
 - [5] Nagasako EM, Oaklander AL, Dworkin RH. Congenital insensitivity to pain: An update. *Pain*. 2003;101:213–9. [[PubMed](#)] [[Google Scholar](#)]
 - [6] Dick PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Dick PJ, Thomas PK, Griffin JW, Low PA, Podreslo JC, editors. *Peripheral Neuropathy*. 17th ed. Philadelphia: Saunders; 1993. pp. 1065–93. [[Google Scholar](#)]
 - [7] Emad MR, Raissi GR. Congenital insensitivity to pain with anhidrosis. *Electromyogr Clin Neurophysiol*. 2003;43:409–41. [[PubMed](#)] [[Google Scholar](#)]



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)